Phoenix Biosciences, Inc. Issued United States Patent for the Clinical Development of PBS119 For HIV/AIDS; New patent marks first step towards clinical studies.
"The approval of this patent is an important step for our development team to move forward with clinical studies of PBS119," said Dr. Robert Keller, Chairman and CEO of Phoenix Biosciences. "Phoenix Biosciences will now aggressively pursue the execution of Phase I/II clinical trials, which will focus on patients experiencing drug resistance."
PBS119 utilizes a novel clinical approach being investigated for safety and clinical efficacy for advanced stage HIV/AIDS disease. PBS119 has been identified as having immune rebuilding potential and antiviral activity. Phoenix Biosciences is currently pursuing initial human studies that will be conducted in compliance with federal clinical trial guidelines.
Dr. Keller has been in clinical practice for the treatment of HIV/AIDS for 25 years and is certified and also sits on the Board of Governors for the Florida Chapter of the American Academy of HIV medicine. In addition, the Consumers' Research Council of America has voted Keller as one of America's top physicians in the field of immunology.
About Phoenix Biosciences, Inc.
Phoenix Biosciences, Inc., an emerging biotech company focused on developing affordable, non-toxic treatments for HIV/AIDS, Hepatitis and viral infections. The company's current lead research compound PBS119 indicates to possess broad spectrum HIV specific qualities. With headquarters in Hollywood, Florida, Phoenix Biosciences, Inc. is a privately-held biotech company. For more information about Phoenix Biosciences, Inc., please email firstname.lastname@example.org or visit www.robkellermd.org.